-
1
-
-
33745508741
-
Perspective - FcRn transports albumin: Relevance to immunology and medicine
-
DOI 10.1016/j.it.2006.05.004, PII S1471490606001463
-
C.L. Anderson Perspective - FcRn transports albumin: Relevance to immunology and medicine Trends Immunol. 27 2006 343 348 (Pubitemid 43963476)
-
(2006)
Trends in Immunology
, vol.27
, Issue.7
, pp. 343-348
-
-
Anderson, C.L.1
Chaudhury, C.2
Kim, J.3
Bronson, C.L.4
Wani, M.A.5
Mohanty, S.6
-
2
-
-
38949192547
-
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
-
R.V. Chari Targeted cancer therapy: Conferring specificity to cytotoxic drugs Acc. Chem. Res. 41 2008 98 107
-
(2008)
Acc. Chem. Res.
, vol.41
, pp. 98-107
-
-
Chari, R.V.1
-
3
-
-
10744222473
-
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
-
DOI 10.1038/nbt832
-
S.O. Doronina Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 2003 778 784 (Pubitemid 36791396)
-
(2003)
Nature Biotechnology
, vol.21
, Issue.7
, pp. 778-784
-
-
Doronina, S.O.1
Toki, B.E.2
Torgov, M.Y.3
Mendelsohn, B.A.4
Cerveny, C.G.5
Chace, D.F.6
DeBlanc, R.L.7
Gearing, R.P.8
Bovee, T.D.9
Siegall, C.B.10
Francisco, J.A.11
Wahl, A.F.12
Meyer, D.L.13
Senter, P.D.14
-
4
-
-
31544441685
-
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
-
DOI 10.1021/bc0502917
-
S.O. Doronina Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity Bioconjug. Chem. 17 2006 114 124 (Pubitemid 43157592)
-
(2006)
Bioconjugate Chemistry
, vol.17
, Issue.1
, pp. 114-124
-
-
Doronina, S.O.1
Mendelsohn, B.A.2
Bovee, T.D.3
Cerveny, C.G.4
Alley, S.C.5
Meyer, D.L.6
Oflazoglu, E.7
Toki, B.E.8
Sanderson, R.J.9
Zabinski, R.F.10
Wahl, A.F.11
Senter, P.D.12
-
5
-
-
0037013439
-
Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages
-
DOI 10.1016/S0960-894X(02)00194-4, PII S0960894X02001944
-
G.M. Dubowchik Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages Bioorg. Med. Chem. Lett. 12 2002 1529 1532 (Pubitemid 34521928)
-
(2002)
Bioorganic and Medicinal Chemistry Letters
, vol.12
, Issue.11
, pp. 1529-1532
-
-
Dubowchik, G.M.1
Radia, S.2
Mastalerz, H.3
Walker, M.A.4
Firestone, R.A.5
Dalton King, H.6
Hofstead, S.J.7
Willner, D.8
Lasch, S.J.9
Trail, P.A.10
-
6
-
-
74949139946
-
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
-
H.K. Erickson Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
-
(2010)
Bioconjug. Chem.
, vol.21
, pp. 84-92
-
-
Erickson, H.K.1
-
7
-
-
6044223544
-
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
-
DOI 10.1158/1078-0432.CCR-04-0789
-
K.J. Hamblett Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 2004 7063 7070 (Pubitemid 39383058)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.20
, pp. 7063-7070
-
-
Hamblett, K.J.1
Senter, P.D.2
Chace, D.F.3
Sun, M.M.C.4
Lenox, J.5
Cerveny, C.G.6
Kissler, K.M.7
Bernhardt, S.X.8
Kopcha, A.K.9
Zabinski, R.F.10
Meyer, D.L.11
Francisco, J.A.12
-
8
-
-
49449087300
-
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
-
J.R. Junutula Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 925-932
-
-
Junutula, J.R.1
-
9
-
-
77957590621
-
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
-
J.R. Junutula Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16 2010 4769 4778
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 4769-4778
-
-
Junutula, J.R.1
-
10
-
-
78651360674
-
Optimizing therapeutic antibody function: Progress with Fc domain engineering
-
E. Kaneko, and R. Niwa Optimizing therapeutic antibody function: Progress with Fc domain engineering BioDrugs 25 2011 1 11
-
(2011)
BioDrugs
, vol.25
, pp. 1-11
-
-
Kaneko, E.1
Niwa, R.2
-
11
-
-
0037068501
-
Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains
-
DOI 10.1021/jm020149g
-
H.D. King Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains J. Med. Chem. 45 2002 4336 4343 (Pubitemid 35025579)
-
(2002)
Journal of Medicinal Chemistry
, vol.45
, Issue.19
, pp. 4336-4343
-
-
King, H.D.1
Dubowchik, G.M.2
Mastalerz, H.3
Willner, D.4
Hofstead, S.J.5
Firestone, R.A.6
Lasch, S.J.7
Trail, P.A.8
-
13
-
-
56449129810
-
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
-
G.D. Lewis Phillips Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68 2008 9280 9290
-
(2008)
Cancer Res.
, vol.68
, pp. 9280-9290
-
-
Lewis Phillips, G.D.1
-
14
-
-
33745684533
-
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
-
DOI 10.1093/protein/gzl013
-
C.F. McDonagh Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19 2006 299 307 (Pubitemid 43999640)
-
(2006)
Protein Engineering, Design and Selection
, vol.19
, Issue.7
, pp. 299-307
-
-
McDonagh, C.F.1
Turcott, E.2
Westendorf, L.3
Webster, J.B.4
Alley, S.C.5
Kim, K.6
Andreyka, J.7
Stone, I.8
Hamblett, K.J.9
Francisco, J.A.10
Carter, P.11
-
15
-
-
54049093284
-
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
-
C.F. McDonagh Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 2913-2923
-
-
McDonagh, C.F.1
-
16
-
-
34247876138
-
Development trends for monoclonal antibody cancer therapeutics
-
DOI 10.1038/nrd2241, PII NRD2241
-
J.M. Reichert, and V.E. Valge-Archer Development trends for monoclonal antibody cancer therapeutics Nat. Rev. Drug Discov. 6 2007 349 356 (Pubitemid 46696550)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.5
, pp. 349-356
-
-
Reichert, J.M.1
Valge-Archer, V.E.2
-
17
-
-
67649886201
-
Potent antibody drug conjugates for cancer therapy
-
P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 3 2009 235 244
-
(2009)
Curr. Opin. Chem. Biol.
, vol.13
, Issue.3
, pp. 235-244
-
-
Senter, P.D.1
-
18
-
-
64949125849
-
Antibody-cytotoxic agent conjugates: Preparation and characterization
-
(xiv)
-
R. Singh, and H.K. Erickson Antibody-cytotoxic agent conjugates: Preparation and characterization Methods Mol. Biol. 525 2009 445 467 (xiv)
-
(2009)
Methods Mol. Biol.
, vol.525
, pp. 445-467
-
-
Singh, R.1
Erickson, H.K.2
-
19
-
-
25444507922
-
Reduction-alkylation strategies for the modification of specific monoclonal antibody bisulfides
-
DOI 10.1021/bc050201y
-
M.M. Sun Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjug. Chem. 16 2005 1282 1290 (Pubitemid 41368132)
-
(2005)
Bioconjugate Chemistry
, vol.16
, Issue.5
, pp. 1282-1290
-
-
Sun, M.M.C.1
Beam, K.S.2
Cerveny, C.G.3
Hamblett, K.J.4
Blackmore, R.S.5
Torgov, M.Y.6
Handley, F.G.M.7
Ihle, N.C.8
Senter, P.D.9
Alley, S.C.10
-
20
-
-
0027218284
-
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
-
P.A. Trail Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261 1993 212 215 (Pubitemid 23265398)
-
(1993)
Science
, vol.261
, Issue.5118
, pp. 212-215
-
-
Trail, P.A.1
Willner, D.2
Lasch, S.J.3
Henderson, A.J.4
Hofstead, S.5
Casazza, A.M.6
Firestone, R.A.7
Hellstrom, I.8
Hellstrom, K.E.9
-
21
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
A. Younes Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
|